Oxford BioMedica Overview
Company Headquarters: Oxford, Oxfordshire, UK
Founded: 1995
Workforce: 330+
Company Working:
Oxford BioMedica is the first company to treat humans with the help of lentivirus and it is a leading player in the global cell and gene therapy market. The company develops and markets LentiVector technology which is widely used by physicians as a part of cell and gene therapy. The company operates in major markets in developed countries such as Americas and Europe. It has 20+ years’ experience in gene therapy segment and the company has conducted trials in more than 140 countries. The company has long term product related partnerships with major pharmaceutical players such as Novartis, orchard therapeutics, Sanofi, GlaxoSmithKline and has research and devleopmnet collaboration with Green Cross Labcell.
Strategy
Oxford BioMedica focuses on growth through both organic as well as inorganic expansion. The company generates its maximum revenue by offering access to the intellectual property, state-of-the-art production facilities and expertise, related to the LentiVector gene delivery platform to the other pharmaceutical companies. Moreover, the company concentrates on major therapeutic areas such as oncology, ophthalmology and CNS disorders for revenue generation. Milestone payments, development and production fees and potential royalties on future product sales are major streams of revenue generation for the company. also, the Long-term agreements with pharmaceutical companies is providing financial stability to the company.
